Added to YB: 2026-06-12
Pitch date: 2026-06-10
RCUS [neutral]
Arcus Biosciences, Inc.
+5.67%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
Market Cap
$2.8B
Pitch Price
$22.05
Price Target
N/A
Dividend
N/A
EV/EBITDA
-5.37
P/E
-6.84
EV/Sales
8.56
Sector
Biotechnology
Category
growth
Show full summary:
GS Healthcare Conference – Recap part 1 (Day 2) - Arcus Biosciences, Inc.
RCUS (overview): Late-stage IO platform at $23.43, focused bet on casdatifan (HIF-2α) for clear cell RCC, a $5-10B+ opportunity, potentially best-in-class vs belzutifan; 80% resources here. Late 2026 catalysts: mono late-line, +zim frontline, triplets, +cabo 2L. Cash into H2 2028.
Read full article (1 min)